Role of Transposable Elements in Septic Immune Aging

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT06809868
Status
Recruiting
Apply to this trial

Conditions

  • Sepsis
  • Sepsis With Acute Organ Dysfunction
  • Sepsis With Multiple Organ Dysfunction (MOD)
  • Sepsis and Septic Shock
  • Sepsis at Intensive Care Unit
  • Sepsis, Septic Shock
  • Sepsis, Severe
  • Sepsis, Severe Sepsis and Septic Shock

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • RNA and DNA Sequencing — GENETIC
    DNA and RNA sequencing will be conducted on both control participants and patients with sepsis who are admitted to the ICU.

Study Details

The goal of this observational study is to learn about how transposable element levels affect the patient outcomes in sepsis. The main questions it aims to answer is: 1. Do transposable elements prematurely age the immune systems of patients with sepsis? 2. Do transposable elements correlate with increased mortality in patients with sepsis in the ICU? 3. Do transposable elements correlate with increased amount of secondary infections in patients with sepsis in the ICU? Participants will have blood drawn from them but will not be subjected to additional interventions.

Key Dates

Start date
Feb 14, 2025
Status verified
Jan 2026
Primary completion
Feb 14, 2028
Completion
Aug 14, 2028

Study Design

Enrollment
116 participants (estimated)

Arms

  • Arm: Patients with Sepsis
    Adult patients (age 18 and older) admitted to the intensive care unit (ICU) meeting Sepsis 3 Criteria.
  • Arm: Healthy Individual Controls
    Healthy individuals not admitted to the hospital.

Primary Outcome Measure

Immune Aging [ Time Frame: 6 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of California, San FranciscoSan FranciscoCalifornia94143
Alexendar R Perez, M.D., Ph.D
[email protected]
415-476-1000
Matthieu Legrand, M.D., Ph.D
[email protected]
415-476-1000
Alexendar R Perez, M.D., Ph.D (PRINCIPAL_INVESTIGATOR)
Judith Hellman, M.D. (PRINCIPAL_INVESTIGATOR)
Matthieu Legrand, M.D., Ph.D (PRINCIPAL_INVESTIGATOR)
Elizabeth Whitlock, M.D. (SUB_INVESTIGATOR)
Orestes Mavrothalassitis, M.D. (SUB_INVESTIGATOR)
Joana Vidigal, Ph.D (SUB_INVESTIGATOR)

Find similar trials in San Francisco, CA

By research site
University of California, San Francisco· San Francisco, CA

Related Studies